FSH, hCG and LH - Therapeutic Proteins for Assisted Reproductive Technology (ART)
Product description The Competitive Intelligence Report FSH, hCG and LH: Therapeutic Proteins for Assisted Reproductive Technology (ART) as of November 2009 provides a competitor analysis in the development pipeline of novel recombinant, transgenic and oral FSH, hCG and LH receptor agonists for treatment of infertility.
Follicle-stimulating hormone (FSH) now has become an established means of ovulation induction (OI) as part of assisted reproductive technology (ART). FSH is used to induce development of multiple follicles in ovulatory women and anovulatory infertile women. The major recombinant FSH products posted 2008 sales of US$ 1.25 bln. Current recombinant (follitropin) as well as highly purified human urinary (urofollitropin) FSH preparations have replaced earlier products with painful IM administrations. Current focus of new development lies on longer-acting and needle-free preparations. The most advanced projects are in registration or late clinical development. Other innovations in FSH R&D are modern production technologies in new expression systems such as plants or transgenic animals. The search for more effective FSH is ongoing and oral FSH receptor agonists have been identified.
Luteinizing Hormone (LH) is being used as part of menotropin preparations together with FSH or alone if profound LH deficiency has been diagnosed. Human choriogonadotropin or chorionic gonadotropin (hCG) aids in final maturation of the eggs and triggers ovulation.
The report describes the market size of major FSH products, provides information on the marketed FSH, hCG and LH preparations and includes a compilation of current active projects in research and development of novel FSH, LH and hCG receptor agonists. Competitor projects are listed in a tabular format providing information on:
- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Company,
- Product Category,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.
Index
- FSH Market: 2008 Sales of Major Products
- Other FSH, hCG and LH Sales Data 2008
- Urinary FSH-Containing Products: Menotropins
- Recombinant Menotropins
- 1st Generation Purified Human Urinary FSH
- 2nd Generation Recombinant Human FSH
- 2nd Generation Rhu FSH in Off-Patent Countries
- New Production Technologies for 2nd Generation Rhu FSH
- 3rd Generation Rhu FSH
- 4th Generation: Oral FSH Receptor Agonists
- Purified Urinary Human Choriogonadotropin (hCG)
- Recombinant Human Choriogonadotropin (rhCG)
- Recombinant Human Luteinizing Hormone (LH)
- Oral LH Receptor Agonist
- About La Merie
Corporate FSH Product Portfolio and R&D Pipelines
- Amega Biotech
- Asterion
- Bharat Serum and Vaccines Ltd
- BioProtein Technologies
- Cinnaris
- Dong-A Pharmaceuticals
- Ferring Pharmaceuticals
- IBSA Institut Biochimique SA
- Intas Biopharmaceuticals
- LG Life Sciences
- Merck Serono
- Protalix Biotherapeutics
- Regeron
- Schering-Plough (ex Organon)
- Shire Pharmaceuticals
- Therapeutic Proteins
- Trophogen
- Vyteris
About Competitor Analysis Series The Competitor Analysis Series delivers NO-FRILLS , but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced. Competitor analysis reports can be purchased as individual products or obtained by subscribing to R&D Pipeline News. R&D Pipeline News is published weekly 50-times a year and each issue contains at least two competitor evaluations. Individual products from the Competitor Analysis Series and R&D Pipeline News are independently elaborated by analysts of La Merie Business Intelligence and distributed by PipelineReview.com.
|
